Toleranzia AB (TOL.ST)
SEK 0.4
(-2.68%)
SEK 0.4
(-2.68%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 160.42 Million SEK | 27.7% |
| 2022 | 125.63 Million SEK | -4.99% |
| 2021 | 132.22 Million SEK | 82.2% |
| 2020 | 72.57 Million SEK | 87.77% |
| 2019 | 38.65 Million SEK | 27.2% |
| 2018 | 30.38 Million SEK | 81.18% |
| 2017 | 16.77 Million SEK | -24.73% |
| 2016 | 22.28 Million SEK | -18.24% |
| 2015 | 27.25 Million SEK | 769.25% |
| 2014 | 3.13 Million SEK | 73.78% |
| 2013 | 1.8 Million SEK | -4.94% |
| 2012 | 1.89 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 156.6 Million SEK | -2.39% |
| 2024 Q3 | 166.46 Million SEK | 6.48% |
| 2024 Q2 | 156.34 Million SEK | -0.17% |
| 2023 Q2 | 121.95 Million SEK | -0.91% |
| 2023 Q1 | 123.08 Million SEK | -2.03% |
| 2023 FY | 160.42 Million SEK | 27.7% |
| 2023 Q4 | 160.42 Million SEK | -2.18% |
| 2023 Q3 | 163.99 Million SEK | 34.47% |
| 2022 Q3 | 125.96 Million SEK | -2.26% |
| 2022 FY | 125.63 Million SEK | -4.99% |
| 2022 Q4 | 125.63 Million SEK | -0.27% |
| 2022 Q1 | 131.53 Million SEK | -0.52% |
| 2022 Q2 | 128.87 Million SEK | -2.02% |
| 2021 Q1 | 71.46 Million SEK | -1.53% |
| 2021 Q4 | 132.22 Million SEK | -3.3% |
| 2021 Q3 | 136.74 Million SEK | 93.46% |
| 2021 FY | 132.22 Million SEK | 82.2% |
| 2021 Q2 | 70.68 Million SEK | -1.09% |
| 2020 Q1 | 36.28 Million SEK | -6.13% |
| 2020 Q2 | 35.35 Million SEK | -2.55% |
| 2020 Q3 | 73.29 Million SEK | 107.3% |
| 2020 Q4 | 72.57 Million SEK | -0.98% |
| 2020 FY | 72.57 Million SEK | 87.77% |
| 2019 Q2 | 27.32 Million SEK | -5.69% |
| 2019 Q1 | 28.96 Million SEK | -4.67% |
| 2019 Q4 | 38.65 Million SEK | 49.5% |
| 2019 Q3 | 25.85 Million SEK | -5.37% |
| 2019 FY | 38.65 Million SEK | 27.2% |
| 2018 Q2 | 32.4 Million SEK | -10.93% |
| 2018 Q4 | 30.38 Million SEK | -2.54% |
| 2018 FY | 30.38 Million SEK | 81.18% |
| 2018 Q3 | 31.17 Million SEK | -3.8% |
| 2018 Q1 | 36.38 Million SEK | 116.94% |
| 2017 Q1 | 20.58 Million SEK | -7.62% |
| 2017 FY | 16.77 Million SEK | -24.73% |
| 2017 Q2 | 19.26 Million SEK | -6.41% |
| 2017 Q4 | 16.77 Million SEK | -7.37% |
| 2017 Q3 | 18.1 Million SEK | -6.03% |
| 2016 Q1 | 26.04 Million SEK | -4.46% |
| 2016 FY | 22.28 Million SEK | -18.24% |
| 2016 Q3 | 23.58 Million SEK | -4.64% |
| 2016 Q2 | 24.72 Million SEK | -5.03% |
| 2016 Q4 | 22.28 Million SEK | -5.5% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | 27.25 Million SEK | 769.25% |
| 2015 Q4 | 27.25 Million SEK | 0.0% |
| 2014 FY | 3.13 Million SEK | 73.78% |
| 2014 Q4 | 3.13 Million SEK | 0.0% |
| 2013 FY | 1.8 Million SEK | -4.94% |
| 2012 FY | 1.89 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -174.201% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -401.319% |
| BioGaia AB (publ) | 2.33 Billion SEK | 93.124% |
| Enzymatica AB (publ) | 125.91 Million SEK | -27.413% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -366.561% |
| Gabather AB (publ) | 2.93 Million SEK | -5362.274% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -119.402% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 74.725% |
| Nanexa AB (publ) | 132.25 Million SEK | -21.299% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -76.544% |
| ODI Pharma AB | 12.27 Million SEK | -1206.942% |
| Orexo AB (publ) | 786.6 Million SEK | 79.605% |
| Probi AB (publ) | 1.55 Billion SEK | 89.653% |
| Swedencare AB (publ) | 9.52 Billion SEK | 98.315% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.783% |
| Vivesto AB | 355.87 Million SEK | 54.921% |